Archives: Speakers

Neelam Gill advises clients and supports Keller and Heckman Partners in the areas of food and drug law and tobacco ande-vapor law, counseling both domestic and international corporations on product and regulatory compliance issuesinvolving the U.S. Food and Drug Administration (FDA). In her tobacco and e-vapor practice, Neelam advises tobacco, e-cigarette, and e-liquid manufacturers, distributors, retailers,suppliers, and trade associations on FDA, state, and global regulatory compliance issues. In the food and drug arena, sheassists clients with a variety of FDA regulatory matters and labeling issues. Neelam’s background and experience in thepharmaceutical industry serves her well in advising clients on the complexities of the Family Smoking Prevention andTobacco Control Act, in particular with quality systems and good manufacturing practices. Neelam advises clients on preparation of FDA submissions, including premarket tobacco product applications (PMTAs),substantial equivalence (SE) reports, tobacco product master

Tom is a Director in the UK Audit & Assurance Analytics team and specialises in working with privately owned and private equity backed businesses. Having worked in analytics for over 12 years, Tom has spent the last 8 supporting the growth of audit quality on external audits through bespoke data modelling and analytics solutions. Tom holds a Bachelor of Science degree in Information Systems Management.

Alexis Nicolaou has almost 30 years’ experience in different industries. He has held C-suite positions in organizations from the Financial Services, Financial Advisory, Media and Technology sectors. He also holds a number of non-exec directorships. Currently, Alexis is the CEO of Block.co, a Blockchain start-up, as well as the Managing Director of Grant Thornton (Blockchain) Cyprus.

Ahmad Namvargolian co-founded Care Access in 2015 which quickly grew into one of the most trusted clinical research companies in the US. Namvargolian’s one core mission for Care Access is to remove barriers in clinical research for sponsors, physicians, and patients; making clinical research accessible to all. This mission was put to test in 2020 when COVID-19 swept through the world causing shutdowns of businesses and clinics. Under Namvargolian’s leadership, Care Access expanded its unique industry solutions and delivered on the largest and most complex decentralized trial to date, taking clinical research directly to patients by deploying “Jump Teams” anywhere in the country and creating pop-up research infrastructure on demand. Having established over 150 “pop-up” sites, Care Access has enrolled over 4,000 patients and conducted over 60,000 home visits.

Prior to Care Access, Namvargolian was a research scientist and earned his Master’s Degree in Public Policy from University of Chicago and Bachelor of Science degree in Bioengineering and Material Science from UC Berkeley.